Matching articles for "Neomycin"
Drugs for Common Eye Disorders
The Medical Letter on Drugs and Therapeutics • December 2, 2019; (Issue 1586)
This issue includes reviews of drugs for glaucoma,
age-related macular degeneration (AMD), bacterial
conjunctivitis, and dry eye disease. Allergic conjunctivitis
is reviewed in a separate...
This issue includes reviews of drugs for glaucoma,
age-related macular degeneration (AMD), bacterial
conjunctivitis, and dry eye disease. Allergic conjunctivitis
is reviewed in a separate issue.
Ciprofloxacin Otic Suspension (Otiprio) for Acute Otitis Externa
The Medical Letter on Drugs and Therapeutics • August 13, 2018; (Issue 1553)
The FDA has approved a 6% otic suspension
formulation of the fluoroquinolone antibiotic
ciprofloxacin (Otiprio – Otonomy) for single-dose
treatment of acute otitis externa (swimmer's
ear) caused by...
The FDA has approved a 6% otic suspension
formulation of the fluoroquinolone antibiotic
ciprofloxacin (Otiprio – Otonomy) for single-dose
treatment of acute otitis externa (swimmer's
ear) caused by Pseudomonas aeruginosa or
Staphylococcus aureus in patients ≥6 months old.
Otiprio was approved earlier for prophylaxis in
children with bilateral otitis media with effusion who
are undergoing tympanostomy tube placement.
Adult Immunization
The Medical Letter on Drugs and Therapeutics • May 7, 2018; (Issue 1546)
The US Advisory Committee on Immunization Practices
(ACIP) recommends routine use of the following
vaccines in adults residing in the US: influenza, tetanus/diphtheria alone (Td) and in combination with...
The US Advisory Committee on Immunization Practices
(ACIP) recommends routine use of the following
vaccines in adults residing in the US: influenza, tetanus/diphtheria alone (Td) and in combination with acellular
pertussis (Tdap), measles/mumps/rubella (MMR),
varicella (VAR), herpes zoster (RZV; ZVL), human
papillomavirus (HPV), and pneumococcal conjugate
(PCV13) and polysaccharide (PPSV23) vaccines. For
adults with certain medical conditions or occupational,
behavioral, or other risk factors, hepatitis A (HepA),
hepatitis B (HepB), meningococcal (MenACWY; MenB),
and Haemophilus influenzae type b (Hib) vaccines are
also recommended. Recommendations for vaccination
against seasonal influenza and vaccination of travelers
are reviewed separately.
Antimicrobial Prophylaxis for Surgery
The Medical Letter on Drugs and Therapeutics • May 23, 2016; (Issue 1495)
Antimicrobial prophylaxis can decrease the
incidence of postoperative surgical site infection
after some procedures. Since the last Medical Letter
article on this subject, consensus guidelines have
been...
Antimicrobial prophylaxis can decrease the
incidence of postoperative surgical site infection
after some procedures. Since the last Medical Letter
article on this subject, consensus guidelines have
been published. Recommendations for prophylaxis
in specific surgical procedures are listed in Table 1.
Mumps Outbreak
The Medical Letter on Drugs and Therapeutics • March 17, 2014; (Issue 1438)
An outbreak of mumps has occurred among students at
Fordham University in New York. All of those who developed
mumps had been vaccinated against the...
An outbreak of mumps has occurred among students at
Fordham University in New York. All of those who developed
mumps had been vaccinated against the disease.
Drugs for Some Common Eye Disorders
The Medical Letter on Drugs and Therapeutics • November 1, 2012; (Issue 123)
Drugs for glaucoma, age-related macular degeneration,
bacterial conjunctivitis, and dry eyes are
reviewed here. Drugs for the treatment of allergic conjunctivitis
will be reviewed in a future issue...
Drugs for glaucoma, age-related macular degeneration,
bacterial conjunctivitis, and dry eyes are
reviewed here. Drugs for the treatment of allergic conjunctivitis
will be reviewed in a future issue of
Treatment Guidelines on Drugs for Allergic Disorders.
Antimicrobial Prophylaxis for Surgery
The Medical Letter on Drugs and Therapeutics • October 1, 2012; (Issue 122)
Antimicrobial prophylaxis can decrease the incidence
of postoperative infection, particularly surgical site
infection, after some procedures. Recommendations
for such prophylaxis are listed in the table that...
Antimicrobial prophylaxis can decrease the incidence
of postoperative infection, particularly surgical site
infection, after some procedures. Recommendations
for such prophylaxis are listed in the table that begins
on page 74. Antimicrobial prophylaxis for dental procedures
to prevent endocarditis was recently discussed
in The Medical Letter.
Rifaximin (Xifaxan 550) for Hepatic Encephalopathy
The Medical Letter on Drugs and Therapeutics • November 1, 2010; (Issue 1350)
The FDA has approved a new 550-mg tablet of rifaximin (Xifaxan – Salix), a minimally absorbed oral
antibiotic, to reduce the risk of recurrent hepatic encephalopathy (HE). A 200-mg tablet has been...
The FDA has approved a new 550-mg tablet of rifaximin (Xifaxan – Salix), a minimally absorbed oral
antibiotic, to reduce the risk of recurrent hepatic encephalopathy (HE). A 200-mg tablet has been available
for treatment of travelers’ diarrhea since 2004.
Drugs for Some Common Eye Disorders
The Medical Letter on Drugs and Therapeutics • January 1, 2010; (Issue 89)
Drugs for glaucoma, age-related macular degeneration, bacterial conjunctivitis, and dry eyes are reviewed here. Ophthalmic drugs can have local and systemic adverse effects. In addition, for some elderly...
Drugs for glaucoma, age-related macular degeneration, bacterial conjunctivitis, and dry eyes are reviewed here. Ophthalmic drugs can have local and systemic adverse effects. In addition, for some elderly patients, the complexity of self-administering numerous ophthalmic drugs may be the limiting factor in their ability to care for themselves. Drugs for the treatment of allergic conjunctivitis will be reviewed in a future issue of Treatment Guidelines on Drugs for Allergic Disorders.
Ophthalmic Besifloxacin (Besivance)
The Medical Letter on Drugs and Therapeutics • December 14, 2009; (Issue 1327)
The FDA has approved the fluoroquinolone besifloxacin 0.6% ophthalmic suspension (Besivance - Bausch & Lomb) for treatment of bacterial conjunctivitis caused by susceptible bacteria. According to the...
The FDA has approved the fluoroquinolone besifloxacin 0.6% ophthalmic suspension (Besivance - Bausch & Lomb) for treatment of bacterial conjunctivitis caused by susceptible bacteria. According to the manufacturer, this product was developed specifically for ophthalmic use in a specialized vehicle designed to prolong contact time on the ocular surface. Besifloxacin is not available for systemic use.
Antimicrobial Prophylaxis for Surgery
The Medical Letter on Drugs and Therapeutics • June 1, 2009; (Issue 82)
Antimicrobial prophylaxis can decrease the incidence of infection, particularly surgical site infection, after certain procedures. Recommendations for prevention of surgical site infection are listed in the...
Antimicrobial prophylaxis can decrease the incidence of infection, particularly surgical site infection, after certain procedures. Recommendations for prevention of surgical site infection are listed in the table that begins on page 48. Antimicrobial prophylaxis for dental procedures to prevent endocarditis is discussed in The Medical Letter 2007; 49:99.
Ophthalmic Azithromycin (AzaSite)
The Medical Letter on Drugs and Therapeutics • February 11, 2008; (Issue 1279)
The FDA has approved azithromycin 1% ophthalmic solution (AzaSite - Inspire) for treatment of bacterial conjunctivitis in patients > 1 year old. It is formulated, according to the manufacturer, in a...
The FDA has approved azithromycin 1% ophthalmic solution (AzaSite - Inspire) for treatment of bacterial conjunctivitis in patients > 1 year old. It is formulated, according to the manufacturer, in a controlled-release delivery system that keeps the drug in the eye for several hours.
Drugs for Some Common Eye Disorders
The Medical Letter on Drugs and Therapeutics • January 1, 2007; (Issue 53)
Drugs for glaucoma, age-related macular degeneration, bacterial and allergic conjunctivitis, and dry eyes are reviewed here. Ophthalmic drugs can have local and systemic adverse effects. In addition, for some...
Drugs for glaucoma, age-related macular degeneration, bacterial and allergic conjunctivitis, and dry eyes are reviewed here. Ophthalmic drugs can have local and systemic adverse effects. In addition, for some elderly patients, the complexity of self-administering numerous ophthalmic drugs may be the limiting factor in their ability to care for themselves.
Antimicrobial Prophylaxis for Surgery
The Medical Letter on Drugs and Therapeutics • December 1, 2006; (Issue 52)
Antimicrobial prophylaxis can decrease the incidence of infection, particularly surgical site infection, after certain procedures. Recommendations for prevention of surgical site infection are listed in this...
Antimicrobial prophylaxis can decrease the incidence of infection, particularly surgical site infection, after certain procedures. Recommendations for prevention of surgical site infection are listed in this article.
Drugs for Parasitic Infections
The Medical Letter on Drugs and Therapeutics • August 16, 2004; (Issue 1189)
Parasitic infections are found throughout the world. With increasing travel, immigration, use of immunosuppressive drugs and the spread of AIDS, physicians anywhere may see infections caused by previously...
Parasitic infections are found throughout the world. With increasing travel, immigration, use of immunosuppressive drugs and the spread of AIDS, physicians anywhere may see infections caused by previously unfamiliar parasites. The table below lists first-choice and alternative drugs for most parasitic infections. The brand names and manufacturers of the drugs are listed in this article.
Antimicrobial Prophylaxis for Surgery
The Medical Letter on Drugs and Therapeutics • April 1, 2004; (Issue 20)
Antimicrobial prophylaxis can decrease the incidence of infection, particularly surgical site infection, after certain operations, but this benefit must be weighed against the risks of toxic and allergic...
Antimicrobial prophylaxis can decrease the incidence of infection, particularly surgical site infection, after certain operations, but this benefit must be weighed against the risks of toxic and allergic reactions, emergence of resistant bacteria, adverse drug interactions, superinfection and cost. Medical Letter consultants generally recommend antimicrobial prophylaxis only for procedures with high infection rates, those involving implantation of prosthetic material, and those in which the consequences of infection are likely to be especially serious.
Ophthalmic Moxifloxacin (Vigamox) and Gatifloxacin (Zymar)
The Medical Letter on Drugs and Therapeutics • March 29, 2004; (Issue 1179)
Two new fluoroquinolone solutions, moxifloxacin 0.5% (Vigamox - Alcon) and gatifloxacin 0.3% (Zymar - Allergan) are now available in the US for ophthalmic use in treatment of bacterial...
Two new fluoroquinolone solutions, moxifloxacin 0.5% (Vigamox - Alcon) and gatifloxacin 0.3% (Zymar - Allergan) are now available in the US for ophthalmic use in treatment of bacterial conjunctivitis.
Drugs for Parasitic Infections
The Medical Letter on Drugs and Therapeutics • April 1, 2002; (Issue 1127)
Superseded--purchase updated Parasitic Infections articleParasitic infections are found throughout the world. With increasing travel, immigration, use of immunosuppressive drugs and the spread of AIDS,...
Superseded--purchase updated Parasitic Infections article
Parasitic infections are found throughout the world. With increasing travel, immigration, use of immunosuppressive drugs and the spread of AIDS, physicians anywhere may see infections caused by previously unfamiliar parasites.
Note: Drugs for Parasitic Infections, revised and updated, is now available to both subscribers and nonsubscribers on our web site. This article, a bi-annual feature of The Medical Letter for many years, will not be published as a printed issue in 2002, but is included in the 16th edition of The Medical Letter Handbook of Antimicrobial Therapy. The handbook is now available and can be ordered by calling customer service at 1-800-211-2769.
Parasitic infections are found throughout the world. With increasing travel, immigration, use of immunosuppressive drugs and the spread of AIDS, physicians anywhere may see infections caused by previously unfamiliar parasites.
Note: Drugs for Parasitic Infections, revised and updated, is now available to both subscribers and nonsubscribers on our web site. This article, a bi-annual feature of The Medical Letter for many years, will not be published as a printed issue in 2002, but is included in the 16th edition of The Medical Letter Handbook of Antimicrobial Therapy. The handbook is now available and can be ordered by calling customer service at 1-800-211-2769.
Drugs for Parasitic Infections
The Medical Letter on Drugs and Therapeutics • January 2, 1998; (Issue 1017)
(Superseded by the 2013 version. Click here to purchase.)Parasitic infections are found throughout the world. With increasing travel, immigration, use of immunosuppressive drugs and the spread of AIDS,...
(Superseded by the 2013 version. Click here to purchase.)
Parasitic infections are found throughout the world. With increasing travel, immigration, use of immunosuppressive drugs and the spread of AIDS, physicians anywhere may see infections caused by previously unfamiliar parasites. The table lists first-choice and alternative drugs for most parasitic infections.
Parasitic infections are found throughout the world. With increasing travel, immigration, use of immunosuppressive drugs and the spread of AIDS, physicians anywhere may see infections caused by previously unfamiliar parasites. The table lists first-choice and alternative drugs for most parasitic infections.
Choice Of Cholesterol-Lowering Drugs
The Medical Letter on Drugs and Therapeutics • January 11, 1991; (Issue 835)
Recent reports indicate that lowering elevated serum cholesterol concentrations not only decreases mortality from coronary artery disease, but may cause regression of atherosclerotic lesions (JP Kane et al,...
Recent reports indicate that lowering elevated serum cholesterol concentrations not only decreases mortality from coronary artery disease, but may cause regression of atherosclerotic lesions (JP Kane et al, JAMA, 264:3007, Dec 19, 1990). Most authorities advise patients with high cholesterol concentrations to eat less saturated and total fat and lose weight. If these measures do not lower serum lipids, drugs are frequently added to the regimen. When drugs are discontinued, serum cholesterol concentrations generally return to pretreatment levels.
Trimethoprim-Polymyxin B for Bacterial Conjunctivitis
The Medical Letter on Drugs and Therapeutics • July 27, 1990; (Issue 823)
Bacterial infections of the conjunctivae are usually self-limited, but topical antimicrobial therapy can be helpful. A solution of trimethoprim sulfate 0.1% with polymyxin B sulfate 10,000 units/ml (Polytrim...
Bacterial infections of the conjunctivae are usually self-limited, but topical antimicrobial therapy can be helpful. A solution of trimethoprim sulfate 0.1% with polymyxin B sulfate 10,000 units/ml (Polytrim - Burroughs Wellcome, distributed by Allergan) was recently marketed in the USA for treatment of superficial ocular bacterial infections.
Choice of Cholesterol-Lowering Drugs
The Medical Letter on Drugs and Therapeutics • September 9, 1988; (Issue 774)
The recent surge of interest in lowering serum cholesterol concentrations has led to vigorous promotion of various hypocholesterolemic drugs in the USA. Since the risk of coronary heart disease is increased in...
The recent surge of interest in lowering serum cholesterol concentrations has led to vigorous promotion of various hypocholesterolemic drugs in the USA. Since the risk of coronary heart disease is increased in patients with high serum cholesterol concentrations, most authorities advise such patients to eat less fat and try to lose weight (The Expert Panel, Arch Intern Med, 148:36, 1988). When these measures fail, cholesterol-lowering drugs are frequently recommended.
Mupirocin - A New Topical Antibiotic
The Medical Letter on Drugs and Therapeutics • May 20, 1988; (Issue 766)
Mupirocin (Bactroban - Beecham), a topical antibiotic formerly called pseudomonic acid, was recently approved by the US Food and Drug Administration for treatment of impetigo. It will be sold as a 2% ointment...
Mupirocin (Bactroban - Beecham), a topical antibiotic formerly called pseudomonic acid, was recently approved by the US Food and Drug Administration for treatment of impetigo. It will be sold as a 2% ointment available only by prescription.